Purchase Order 75N93020P00935

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Biolegend, Inc. for COVID-19 reagents with a ceiling value of $26,145.00, effective April 9, 2021. Performance is located in San Diego, California, with an ultimate completion date of May 7, 2021. The order is firm fixed price with no small business set-aside.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Biolegend, Inc. for $10,810.00 on August 18, 2020. The order covers biomedical reagents and research materials to be supplied from San Diego, California with a completion date of September 16, 2020. No set-aside applied.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Biolegend, Inc. valued at $6,892.26 on August 9, 2018, for antibodies. The order was issued as a firm fixed-price acquisition with no set-aside. Place of performance is San Diego, California. The ultimate completion date is August 8, 2019. The purchase order was issued to de-obligate expiring FY'18 funds.</p>

<p>The National Institute of Allergy and Infectious Diseases (NIAID) awarded a purchase order to Biolegend, Inc. for antibodies with a ceiling value of $12,042.50 on September 2, 2020, with an ultimate completion date of October 2, 2020. No set-aside was used. Performance takes place in San Diego, California. The order is firm fixed price for commercial antibody products supplied by Biolegend, a biomedical reagents manufacturer.</p>

This is a $98,517.25 firm-fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Biolegend, Inc., a for-profit manufacturer of biomedical reagents, antibodies, and other products supporting life science research and drug discovery. The contract, awarded on January 28, 2021, is for the procurement of COVID-19 research antibodies, with a period of performance through January 26, 2022....

The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, awarded a firm-fixed-price purchase order contract worth $8,377.50 to Biolegend, Inc., a for-profit manufacturer of biomedical reagents and antibodies. The contract is for the delivery of &quot;Brilliant Violet Anti-Human Antibodies&quot; to support the agency's research efforts. Biolegend, Inc. is a subsidiary of the parent company Revvity Inc. This contract...

The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $25,000 purchase order to Biolegend, Inc., a medical division of Revvity Inc., to deliver Brilliant Violet 650TM anti-human CD197. The firm fixed price contract runs from September 20, 2023 through December 29, 2023 for the provision of this product to support NIH research efforts. No major subcontractors or set aside designations were identified. Biolegend...

BioLegend, Inc. was awarded a $10,635.85 firm fixed-price purchase order by the National Institute of Allergy and Infectious Diseases (NIAID) on April 21, 2020, for the supply of antibodies. The contract, which carries no set-aside designation, was designated as a National Interest Action related to Coronavirus COVID-19 response efforts and is scheduled for completion by May 20, 2020. The work will be performed at BioLegend's facility in San Diego, California. BioLegend is a San Diego-based...

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Becton, Dickinson and Company (BD Biosciences) valued at $11,535.00 on July 29, 2020, for Human IL-4 (Clone MP4-25D2) BB700 antibody reagent, 1 milligram quantity. Performance location is San Jose, California. The order was completed on August 28, 2020. The award was designated under the Coronavirus COVID-19 National Interest Action Code.</p>

This firm-fixed-price federal contract award, valued at $25,200.00, was made by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services, to the prime contractor Biolegend, Inc. The contract is for the provision of 144 units of Brilliant Violet 421 Anti-Human CD4 reagents, which are used to support biomedical research efforts across multiple federal agencies. Biolegend is a for-profit manufacturer and supplier of specialized...